DTx Pharma Expands Footprint in San Diego with New Office and Lab Space
SAN DIEGO, May 20, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers [...]
DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS
-DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide- SAN DIEGO, May 13, 2020 /PRNewswire/ -- DTx [...]
DTx Pharma Completes $10.6M Series A Financing
DTx Pharma announced today the final closing of a Series A financing totaling $10.6 million dollars. The round was led by San Diego-based FBV [...]
Partnership with DTx Pharma to optimize antisense oligonucleotides as a gene therapy for CMT1A
The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth, today announced it has partnered with DTx Pharma, an RNA medicines company [...]
DTx receives 3rd NIH SBIR in 2019: Targeting Tau in Neurodegenerative Disease
DTx received a notice of award in September for our first CNS focused grant, targeting the Tau gene/protein implicated in FTLD’s such as PSP as [...]
DTx Pharma to Attend Biotech Showcase at 2019 JP Morgan Healthcare Conference; Selected to Participate in West Coast Innovators Pitch Challenge
San Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, today announced that it will attend the 2019 [...]
DTx Pharma was named by the San Diego Venture Group as one of their 30 Cool Companies of 2018
Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, was named by the San Diego Venture Group (SDVG) [...]
DTx Pharma to Attend 2018 BIO International Convention
San Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, today announced that it will attend the 2018 [...]
DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, is pleased to announce that Jeff Friedman, MD/PhD has been appointed Chief Operating Officer, effective immediately
"Jeff is a valuable addition to the DTx Pharma team. He has served as both a scientific and business advisor since the inception of DTx [...]
DTx Pharma accepted into CONNECT Springboard Accelerator Program
DTx Pharma, a RNA-based therapeutics company, announced that it has been accepted into the prestigious CONNECT mentoring program. CONNECT is a program whose graduates have [...]